Session Title: Quick Fire Free Paper Session 04
Session Date/Time: Sunday 29/09/2013 | 11:00-13:00
Paper Time: 11:40
Venue: Hall C (Level 1)
First Author: F.Batioglu TURKEY
Co Author(s): S. Demirel O. Yan?k E. Ozmert
To determine changes and need to monitor intraocular pressure (IOP) changes following intravitreal injection of ranibizumab. To report the trends in intraocular pressures (IOP) in the patients with pre existing glaucoma and pseudophakia.
Large, retrospective case series
IOP values prior to first injection and at first, third, sixth, ninth, and twelfth injections were recorded. The main outcome measures of this study were to analyze IOP changes between 30 minutes and 24 hours at the same injection within each diagnostic groups, to analyze change in 30 minutes and 24 hours IOP values respectively throughout repated injections, and to assess whether repeated intravitreal anti-VEGF injections cause cumulative increase in IOP. The secondary outcome measures was to observe whether there was any effect of pseudophakia and pre-existing glaucoma on IOP change during intravitreal anti-VEGF injections.
The mean number of injections was 4.81± 2,7 with a minimum of 3 to a maximum of 18 injections. The mean IOP prior to the first intravitreal anti-VEGF therapy was 15.11±2.8 mmHg (9- 25 mmHg) and it was 14.66±2.8 mmHg (9- 22 mmHg) at the last visit. The decrease in the mean IOP values from 30 minutes to 24 hours was statistically significant for each follow-up visit. When the 30-minute IOP values were compared to each other for all follow-up visits, there was no statistical significant difference or cumulative increase in IOP values of each diagnostic groups throughout repetitive injections (p=0.3310).
Pseudophakic patients had lower mean IOP scores than phakic group, at the 30 minutes of all injection visits. Pre-existing glaucoma may be a potential risk factor for uncontrolled IOP spikes immediately after intravitreal anti-VEGF injection but this effect is usually transient and does not cause long-term problems and anti-VEGF injections can be performed safely under close monitorising.